Researchers from the University of Houston and University of Michigan in Ann Arbor have developed a dual-target drug designed to overcome immunotherapy resistance in pancreatic cancer.
The research team developed SH-273 and a nanoparticle version, Nano-273, to boost immune system activity against pancreatic ductal adenocarcinoma, according to a May 27 news release. The cancer type has a five-year survival rate of 13%.
The study, published April 28 in Nature Cancer, found that combining STING activation with PI3Kγ inhibition reduced regulatory B cells that can block immune responses against tumors.
In mouse models and patient-derived human cells, Nano-273 improved survival to 201 days, reduced tumor metastasis and invasion in the lungs, and did not show toxicity in animals, the researchers said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
